MDRNA last week reported a jump in its first-quarter loss as a drop in revenues more than offset a decrease in operating costs.

MDRNA's net loss in the quarter was $9.5 million, or $0.20 per share, versus a year-ago loss of $7.3 million, or $0.23 per share.

Revenues in the quarter plummeted $14 million to $200,000, reflecting the receipt of milestones and licensing fees from partners Novartis, Roche, and Amylin Pharmaceuticals in the year-ago quarter, which were not received this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.